Nilotinib Induced Keratosis Pilaris Atrophicans

A 46-year-old man with chronic myelogenous leukemia (CML) developed keratosis pilaris atrophicans, characterized by red bumps and patchy hair loss, after starting nilotinib, a second-generation tyrosine kinase inhibitor. This case highlighted that cutaneous reactions, including pruritus, rash, dry skin, and alopecia, were common non-hematologic adverse effects of nilotinib. The patient's skin became dry and rough, with follicular accentuation and thinning of the eyebrows. It was important to distinguish these reactions from more severe drug hypersensitivity eruptions and to classify them based on morphology for better management.